Different patterns of technetium-99m sestamibi uptake in multiple myeloma(366 views) Pace L, Catalano L, Pinto A, De Renzo A, Di Gennaro F, Califano C, Del Vecchio S, Rotoli B, Salvatore M
Affiliations: Cattedra di Medicina Nucleare, Dipto. Sci. Biomorfologiche F., Università Federico II, Napoli, Italy
Ctro. C.N.R. per la Med. Nucleare, Napoli, Italy
Cattedra di Ematologia, Dipto. di Med. Clin. e Sperimentale, Università Federico II, Napoli, Italy
Ctro. C. N. R. per la Med. Nucleare, Napoli, Italy
References: Hubner, K.F., Andrews, G.A., Hayes, R.L., Poggenburg, J.K., Solomon, A., The use of rare earth radionuclides and other hone seeker in the evaluation of bone lesions in patients with multiple myeloma or solitary plasmacytoma (1977) Radiology, 125, pp. 171-17
Kanoh, T., Ohno, T., Uehino, H., Amamoto, I., Torizuka, K., Avid uptake of 67-Ga in multiple myeloma. An additional indicator of the aggressive phase (1987) Clin Nucl Med, 12, pp. 482-484
Ludwig, H., Kupman, W., Sinzinger, H., Radiography and bone scintigraphy in multiple myeloma: A comparative analysis (1982) Br J Radiol, 55, pp. 173-181
Scutellari, P.N., Spanedda, R., Feggi, L.M., Cervi, P.M., The value and limitations of total body scan in the diagnosis of multiple myeloma: A comparison with conventional radiography (1985) Hematologica, 70, pp. 136-142
Durie, B.G.M., Waxman, A., Jochelson, M., Giles, F.J., Hamburg, G., Asedon, M., Technetium-99m-MIBI scanning in multiple myeloma (MM) (1994) Proc Am Soc Clin Oncol, 13, p. 411
Malpas, J.S., Tirovola, E.B., Biassoni, L., Kaleva, N., Kouykin, V., Britton, K.E., Myeloma imaging with Te-99m MIBI (1995) Proc. 5th International Workshop on Multiple Myeloma, 3, p. 120. , La Baule, France, 10-13 September
Unlu, M., Haznedar, R., Atavci, S., Inanir, S., Targut, B., Detection of bone lesion in multiple myeloma using Tc-99m MIBI scintigraphy (1995) Eur J Nucl Med, 22 (SUPPL.), p. 739
Adams, B.K., Fataar, A., Nizami, M.A., Technetium-99m-sestamibi uptake in myeloma (1996) J Nucl Med, 37, pp. 1001-1002
Biassoni, L., Tirovola, E., Kaleva, N., Kouykin, V., Britton, K.E., Myeloma imaging with Tc99m MIBI (1995) Eur J Nucl Med, 22, p. 856
Nquyen, K., Waxman, A., Grupta, J., Delriego, J., Durie, B., Look, R., Kim, S., Jochelson, M., Characteristics of Tc99m methoxyisobutylisonitrile (MIBI) in the evaluation of multiple myeloma (1996) J Nucl Med, 37, pp. 267P
El-Shirbiny, A.M., Eung, H., Imbriaco, M., Michaeli, J., Macapinlac, H., Larson, S.M., Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma (1997) J Nucl Med, 38, pp. 1208-1210
Durie, B.G.M., Salmon, S.E., A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival (1975) Cancer, 36, pp. 842-854
Hassan, I., Sahweil, A., Constantinides, C., Mahmoud, A., Nair, M., Abdel-Dayem, H., Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl-isonitrile in benign and malignant lesions in the lungs (1989) Clin Nucl Med, 14, pp. 333-340
Kipatchi, M.T., Tastekin, G., Turgut, M., Preoperative localization of parathyroid carcinoma using 99mTc-MIBI (1993) Clin Nucl Med, 18, pp. 217-219
Kao, C.H., Wang, S.J., Liu, T.J., The use of technetium-99m-methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses (1994) Eur J Nucl Med, 21, pp. 432-436
Caner, B., Kitapci, M., Aras, T., Erbengi, G., Ugur, O., Bekdik, C., Increased accumulation of 2-methoxyisobutylisonitrile technetium in osteosarcoma and its metastatic lymph nodes (1991) J Nucl Med, 32, pp. 1977-1978
Piwnica-Worms, D., Holman, L., Non-cardiac applications of hexakis (alkylisonitrile) 99mTc complexes (1990) J Nucl Med, 31, pp. 1166-1167
Chiu, M.L., Kronauge, J.F., Piwnica-Worms, D., Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium in cultured mouse fibroblast (1990) J Nucl Med, 31, pp. 1646-1653
Del Vecchio, S., Ciarmiello, A., Potena, M.I., In vivo detection of multidrug-resistant (MDR1) phenotype by 99mTc-sestamibi scan in untreated breast cancer patients (1997) Eur J Nucl Med, 24, pp. 150-159
Salomon, S.E., Cassady, J.R., Plasma cell neoplasm (1997) Cancer - Principles and Practice of Oncology, pp. 2344-2387. , De Vita VT Jr, Hellman SH, Rosenberg SA, eds. Philadelphia New York: Lippincott-Raven
Hubner, K. F., Andrews, G. A., Hayes, R. L., Poggenburg, J. K., Solomon, A., The use of rare earth radionuclides and other hone seeker in the evaluation of bone lesions in patients with multiple myeloma or solitary plasmacytoma (1977) Radiology, 125, pp. 171-17
Scutellari, P. N., Spanedda, R., Feggi, L. M., Cervi, P. M., The value and limitations of total body scan in the diagnosis of multiple myeloma: A comparison with conventional radiography (1985) Hematologica, 70, pp. 136-142
Durie, B. G. M., Waxman, A., Jochelson, M., Giles, F. J., Hamburg, G., Asedon, M., Technetium-99m-MIBI scanning in multiple myeloma (MM) (1994) Proc Am Soc Clin Oncol, 13, p. 411
Malpas, J. S., Tirovola, E. B., Biassoni, L., Kaleva, N., Kouykin, V., Britton, K. E., Myeloma imaging with Te-99m MIBI (1995) Proc. 5th International Workshop on Multiple Myeloma, 3, p. 120. , La Baule, France, 10-13 September
Adams, B. K., Fataar, A., Nizami, M. A., Technetium-99m-sestamibi uptake in myeloma (1996) J Nucl Med, 37, pp. 1001-1002
El-Shirbiny, A. M., Eung, H., Imbriaco, M., Michaeli, J., Macapinlac, H., Larson, S. M., Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma (1997) J Nucl Med, 38, pp. 1208-1210
Durie, B. G. M., Salmon, S. E., A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival (1975) Cancer, 36, pp. 842-854
Kipatchi, M. T., Tastekin, G., Turgut, M., Preoperative localization of parathyroid carcinoma using 99mTc-MIBI (1993) Clin Nucl Med, 18, pp. 217-219
Kao, C. H., Wang, S. J., Liu, T. J., The use of technetium-99m-methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses (1994) Eur J Nucl Med, 21, pp. 432-436
Chiu, M. L., Kronauge, J. F., Piwnica-Worms, D., Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium in cultured mouse fibroblast (1990) J Nucl Med, 31, pp. 1646-1653
Salomon, S. E., Cassady, J. R., Plasma cell neoplasm (1997) Cancer - Principles and Practice of Oncology, pp. 2344-2387. , De Vita VT Jr, Hellman SH, Rosenberg SA, eds. Philadelphia New York: Lippincott-Raven
Different patterns of technetium-99m sestamibi uptake in multiple myeloma
Technetium-99m 2-methoxyisobutylisonitrile (99mTc-MIBI) has been proposed as a potential tracer in patients with multiple myeloma (MM). The aims of this study were to evaluate the incidence of various patterns of diffuse 99mTc-MIBI uptake in patients with MM, to assess their relationship with clinical status and stage of disease, and to try to clarify the meaning of the diffuse bone marrow uptake of 99mTc-MIBI. Thirty-nine consecutive patients with MM were studied. Twenty-nine of these patients had active disease (13 in stage I, ten in stage II, and six in stage III) and ten were in remission after chemotherapy. Anterior and posterior whole-body scans were obtained 10 min after i.v. injection of 555 MBq of 99mTc-MIBI. The scans were classified as showing: pattern N, when only physiological uptake was present; pattern D, when diffuse bone marrow uptake was observed; pattern F, when areas of focal uptake of the radiotracer were evident; or pattern D+F when both D and F patterns were observed. Diffuse bone marrow uptake was scored according to extension and intensity. Seven of the 39 patients (18%) showed pattern N, 18 (46%) pattern D, 2 (5%) pattern F, and 12 (31%) pattern D+F. Of the 32 patients with a positive 99mTc-MIBI scan (i.e. showing pattern D, F or D+F), 29 (91%) had active disease. Only three patients in remission showed pattern D, but with a very low bone marrow uptake score. Both extension and intensity of diffuse bone marrow uptake correlated with the amount of the monoclonal component and the percentage of bone marrow plasma cells. The distribution of the 99mTc-MIBI uptake patterns differed among patients in different stages of disease. Using as criteria for advanced stage the presence of either focal uptake (pattern F or D+F) or pattern D with a high score, high (90%) diagnostic accuracy was obtained. In conclusion, the patterns of 99mTc-MIBI uptake in patients with MM are related to both the clinical status and the stage of disease. The presence of focal uptake or of intense diffuse bone marrow uptake suggests that the patient has active and advanced stage disease, while a negative scan in a patient with MM clearly indicates remission.
Different patterns of technetium-99m sestamibi uptake in multiple myeloma
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(288 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(730 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote